From Free Binding Energy Calculations of SARS-CoV-2—Receptor Interactions to Cellular Immune Responses

Our study focuses on free energy calculations of SARS-CoV-2 spike protein receptor binding motives (RBMs) from wild type and variants of concern (VOCs), with emphasis on SARS-CoV-2 Omicron. Our computational analysis underlines the occurrence of positive selection processes that specify Omicron host adaption and bring changes on the molecular level into context with clinically relevant observations. Our free energy calculation studies regarding the interaction of Omicron’s RBM with human angiotensin converting enzyme 2 (hACE2) indicate weaker binding to the receptor than Alpha’s or Delta’s RBMs. Upon weaker binding, fewer viruses are predicted to be generated in time per infected cell, resulting in a delayed induction of danger signals as a trade-off. Along with delayed immunogenicity and pathogenicity, more viruses may be produced in the upper respiratory tract, explaining enhanced transmissibility. Since in interdependence on the human leukocyte antigen type (HLA type), more SARS-CoV-2 Omicron viruses are assumed to be required to initiate inflammatory immune responses, and because of pre-existing partial immunity through previous infections and/or vaccinations, which mostly guard the lower respiratory tract, overall disease severity is expected to be reduced.

[1]  M. Lipsitch,et al.  Clinical outcomes among patients infected with Omicron (B.1.1.529) SARS-CoV-2 variant in southern California , 2022, medRxiv.

[2]  Weiliang Zhu,et al.  SARS-CoV-2 Omicron RBD shows weaker binding affinity than the currently dominant Delta variant to human ACE2 , 2022, Signal Transduction and Targeted Therapy.

[3]  William T. Harvey,et al.  The hyper-transmissible SARS-CoV-2 Omicron variant exhibits significant antigenic change, vaccine escape and a switch in cell entry mechanism , 2022, medRxiv.

[4]  N. Volkow,et al.  Comparison of outcomes from COVID infection in pediatric and adult patients before and after the emergence of Omicron , 2022, medRxiv.

[5]  G. Gao,et al.  Receptor binding and complex structures of human ACE2 to spike RBD from omicron and delta SARS-CoV-2 , 2022, Cell.

[6]  J. Bhiman,et al.  Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South Africa , 2021, medRxiv.

[7]  S. Subramaniam,et al.  SARS-CoV-2 Omicron Variant: ACE2 Binding, Cryo-EM Structure of Spike Protein-ACE2 Complex and Antibody Evasion , 2021, bioRxiv.

[8]  L. Trautmann,et al.  Antibody Response and Variant Cross-Neutralization After SARS-CoV-2 Breakthrough Infection. , 2021, JAMA.

[9]  M. Jawaid,et al.  Simulation of the omicron variant of SARS-CoV-2 shows broad antibody escape, weakened ACE2 binding, and modest increase in furin binding , 2021, bioRxiv.

[10]  F. Baldanti,et al.  Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant , 2021, BMC Medicine.

[11]  M. Gur,et al.  Omicron BA.1 and BA.2 variants increase the interactions of SARS-CoV-2 spike glycoprotein with ACE2 , 2021, bioRxiv.

[12]  H. Woo,et al.  Omicron: A heavily mutated SARS-CoV-2 variant exhibits stronger binding to ACE2 and potently escape approved COVID-19 therapeutic antibodies , 2021, bioRxiv.

[13]  Weiliang Zhu,et al.  The effect of the multiple mutations in Omicron RBD on its binding to human ACE2 receptor and immune evasion: an investigation of molecular dynamics simulations , 2021 .

[14]  Suresh Kumar,et al.  Omicron and Delta Variant of SARS-CoV-2: A Comparative Computational Study of Spike protein , 2021, bioRxiv.

[15]  S. Karim,et al.  Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic , 2021, The Lancet.

[16]  I. Torjesen.  Covid-19: Omicron may be more transmissible than other variants and partly resistant to existing vaccines, scientists fear , 2021, BMJ.

[17]  F. Fratev.  N501Y and K417N Mutations in the Spike Protein of SARS-CoV-2 Alter the Interactions with Both hACE2 and Human-Derived Antibody: A Free Energy of Perturbation Retrospective Study , 2021, J. Chem. Inf. Model..

[18]  Soohyun Kim,et al.  SARS-CoV-2 Delta (B.1.617.2) Variant: A Unique T478K Mutation in Receptor Binding Motif (RBM) of Spike Gene , 2021, Immune network.

[19]  N. Maffulli,et al.  Association between HLA genotypes and COVID-19 susceptibility, severity and progression: a comprehensive review of the literature , 2021, European Journal of Medical Research.

[20]  Oriol Vinyals,et al.  Highly accurate protein structure prediction with AlphaFold , 2021, Nature.

[21]  E. Holmes,et al.  After the pandemic: perspectives on the future trajectory of COVID-19 , 2021, Nature.

[22]  Fatmah M A Naemi,et al.  Association between the HLA genotype and the severity of COVID‐19 infection among South Asians , 2021, Journal of medical virology.

[23]  A. García-Sastre,et al.  The N501Y mutation in SARS-CoV-2 spike leads to morbidity in obese and aged mice and is neutralized by convalescent and post-vaccination human sera , 2021, medRxiv.

[24]  M. H. Cheng,et al.  Impact of South African 501.V2 Variant on SARS-CoV-2 Spike Infectivity and Neutralization: A Structure-based Computational Assessment , 2021, bioRxiv.

[25]  Carl A. B. Pearson,et al.  Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England , 2021, Science.

[26]  T. Korcsmáros,et al.  SARS-CoV-2 Causes a Different Cytokine Response Compared to Other Cytokine Storm-Causing Respiratory Viruses in Severely Ill Patients , 2020, Frontiers in Immunology.

[27]  L. Guruprasad.  Human SARS CoV‐2 spike protein mutations , 2020, Proteins.

[28]  Yan Li,et al.  Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy , 2020, Science.

[29]  Jesse D. Bloom,et al.  Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding , 2020, bioRxiv.

[30]  Jianhong Lu,et al.  The MERS-CoV Receptor DPP4 as a Candidate Binding Target of the SARS-CoV-2 Spike , 2020, iScience.

[31]  Linqi Zhang,et al.  Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor , 2020, Nature.

[32]  G. Herrler,et al.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.

[33]  M. Glocker,et al.  In silico Epitope Mapping of Glucose-6-Phosphate Isomerase:A Rheumatoid Arthritis Autoantigen , 2017 .

[34]  Linqi Zhang,et al.  Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4 , 2013, Cell Research.

[35]  Marianne Rooman,et al.  BeAtMuSiC: prediction of changes in protein–protein binding affinity on mutations , 2013, Nucleic Acids Res..

[36]  S. Harrison,et al.  Structure of SARS Coronavirus Spike Receptor-Binding Domain Complexed with Receptor , 2005, Science.

[37]  Chengsheng Zhang,et al.  Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2 , 2005, The EMBO journal.

[38]  P. Matzinger.  The Danger Model: A Renewed Sense of Self , 2002, Science.

[39]  J. Dushoff,et al.  Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa , 2021 .